
pmid: 1329172
AbstractThe study duration in a clinical trial with censored survival data is the sum of the accrual duration, which determines the sample size in a traditional sense, and the follow‐up duration, which more or less controls the number of events to be observed. We propose a design procedure for determining the study duration or for calculating the power in a group sequential clinical trial with censored survival data and possibly unequal patient allocation between treatments, adjusting for stratified randomization. The group sequential method is based on the use function approach. We describe a clinical trial recently activated by the Eastern Cooperative Oncology Group for an illustration of the proposed procedure.
Survival Rate, Clinical Trials as Topic, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Normal Distribution, Humans, Combined Modality Therapy, Survival Analysis, Follow-Up Studies, Randomized Controlled Trials as Topic
Survival Rate, Clinical Trials as Topic, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Normal Distribution, Humans, Combined Modality Therapy, Survival Analysis, Follow-Up Studies, Randomized Controlled Trials as Topic
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 9 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
